The high prevalence of sleep disturbance in neurodegenerative and psychiatric conditions is often interpreted as evidence for both sleep's sensitivity to and causal involvement in brain pathology. Nevertheless, how and which aspects of sleep contribute to brain function remains largely unknown. This review provides a critical evaluation of clinical and animal literature describing sleep and circadian disturbances in two distinct conditions and animal models thereof: Alzheimer's disease (AD) and schizophrenia. Its goal is to identify commonalities and distinctiveness of specific aspects of sleep disturbance and their relationship to symptoms across conditions. Despite limited standardisation, data imply that reductions in sleep continuity and alterations in sleep timing are common to AD and schizophrenia, whereas reductions in REM sleep and sleep spindle activity appear more specific to AD and schizophrenia, respectively. Putative mechanisms underlying these alterations are discussed. A standardised neuroscience based quantification of sleep and disease-independent assessment of symptoms in patients and animal models holds promise for furthering the understanding of mechanistic links between sleep and brain function in health and disease.
Introduction
This review is inspired by and is a critical reaction to the Innovative Medicines Initiative PRISM project, the focus of this Special Edition (Kas et al. 2018 , this edition; http://www.imi.europa.eu/projectsresults/project-factsheets/prism). While not concentrating on sleep biology per se, PRISM is an early practical attempt to redefine traditionally defined diagnoses of central nervous system (CNS) disease (in this case Alzheimer's disease and schizophrenia) based on more quantitative biological phenotypes. The work of PRISM builds on other efforts such as the Research Domain Criteria initiative (Insel et al., 2010) , a NIMH-sponsored attempt to develop a modern, research-based taxonomy of mental disease. Such effort is bolstered by an increasing scientific uneasiness that traditional neuropsychiatric diagnostic boundaries may be impeding discovery of more impactful therapies for patients. The goal of PRISM is of appreciable scientific merit; however, such reconstructive approaches are not without technical and conceptual challenge. The aim of this review is to exemplify sleep disturbance as a potential quantitative biological phenotype in this context, and to assess the current utility of such work for redefining diagnostic boundaries of Alzheimer's disease (AD) and schizophrenia and the understanding of the contribution of sleep disturbance to symptoms across these diseases.
Within the general population, the subjective experience of sleep and its disturbance is one of the most significant determinants of quality of life (Strine and Chapman, 2005) . Sleep disturbance is also amongst the most prevalent neuropsychiatric symptoms (NPS) in a wide range of psychiatric and neurological disorders, such as AD, Parkinson's disease, major depression, bipolar disorder and schizophrenia (Baglioni et al., 2016; Sutton, 2014) . However, matters of on-going debate are whether sleep disturbance should be considered primary or secondary components of such disorders, to what extent it contributes to onset and T exacerbation of other symptoms, and whether it can be used as biomarker of the diseases (Musiek and Holtzman, 2016; Winokur, 2015; Yaffe et al., 2014; Kang et al., 2017) . How sleep disturbance has actually been measured in previous studies is a vital consideration, as several approaches have been used with different limitations in their ability to provide information of appropriate complexity and utility. This review will argue that an attempt to delineate a more biologically driven reclassification of neurological and psychiatric diseases, such as AD and schizophrenia, must pay more attention to parameters of sleep disturbance and make more effort to measure these parameters at the appropriate level of resolution in a co-ordinated manner in conjunction with neuropsychiatric assessment.
Alzheimer's disease and schizophrenia: clinical presentation and current diagnosis

Alzheimer's disease
First described by Alois Alzheimer in 1907 (Cipriani et al., 2011) , AD is a progressive neurodegenerative condition that represents the majority of diagnosed dementia cases. A classic presentation of AD would typically be an older person who complains of subjective memory problems, or a significant other/carer does on their behalf (Albert et al., 2011) . These problems may initially be related to episodic or autobiographical memories, but over a period of years will eventually involve most aspects of function necessary for daily living (https://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp, accessed 8/5/18; El Haj et al., 2015; Tromp et al., 2015) . Clinical diagnosis of probable AD is currently based on presentation of symptoms. Diagnosis is principally determined by the progressive worsening of memory accompanied by changes in other cognitive domains, such as language, motor skills or perception (McKhann et al., 1984) , which cannot be explained by other factors. Furthermore, other NPS such as apathy, avolition and emotional and social withdrawal may be prominent features in AD (Reichman and Negron, 2001) . Recent studies pointed that NPS, including sleep disturbance, represent a risk factor to develop dementia (Bidzan et al., 2017; Frohnhofen et al., 2017) . Neurologists have long recognised that AD is by no means a unitary disease that afflicts all patients equivalently, with empirical evidence suggesting the existence of several subtypes, such as posterior cortical and logopenic aphasic variants (Elahi and Miller, 2017) .
In-life diagnosis of probable AD can be confirmed post-mortem by the presence in the brain of amyloid plaques and tau neurofibrillary tangles (Bourdenx et al., 2017) . Findings suggest that deposition of neurofibrillary tangles relates more consistently with symptomatic complaints than do amyloid plaques (Theofilas et al., 2017) . Plaques and tangles largely show stereotypical patterns of deposition (Braak and Braak, 1991) , suggesting that some brain regions and/or networks may be more vulnerable to pathology (Arendt et al., 2017; Gotz et al., 2009; Hu et al., 2017; Oh et al., 2016; Stranahan and Mattson, 2010; Wang et al., 2016) . There is increasing evidence suggesting that tangles spread throughout the brain in a manner consistent with underlying neuroanatomical connectivity (Hanger et al., 2014; Jucker and Walker, 2013; Medina and Avila, 2014; Nizynski et al., 2017) . Research exploring the propagative nature of AD neuropathology has been greatly facilitated by the recent availability of both amyloid and tau protein PET ligands (Blennow et al., 2015; Dani et al., 2016; Mathis et al., 2017; Roberts et al., 2017) , which now allow for in vivo longitudinal assessment of neuropathology in patients. Future diagnosis (and prognostic evaluation) of AD will certainly employ more sophisticated use of amyloid and tau PET imaging technologies to determine subtypes of disease based on patterns and progression of neuropathological depositions (Jack et al., 2016) . Such work is only just beginning to impact upon a potential redefinition of AD diagnostic boundaries.
Schizophrenia
Descriptions of the schizophrenic syndrome have been prevalent in the scientific literature for more than a century (Fox, 1978; Hoenig, 1983; Snowden, 2009) . Notably, the term dementia praecox ("premature dementia") has been historically used to describe the disease (Noll, 2011) . Schizophrenia is a relatively non-progressive neuropsychiatric disorder characterised and diagnosed by a constellation of symptoms (American Psychiatric Association, 2018) . A classic presentation would be a teenager or young adult exhibiting signs of prodromal psychosislike behaviour (e.g., unusual thoughts, perceptual abnormalities, social withdrawal) that may lead to "first break", i.e., a full-blown episode of psychosis requiring medical intervention (Birchwood et al., 1998; . The prognosis of such patients will vary depending on responsiveness to treatment and other symptoms that may subsequently emerge (Alvarez-Jimenez et al., 2016; Diaz-Caneja et al., 2015; Millan et al., 2016; Zhu et al., 2017a, b) . Patients often have little insight into their illness (Amador et al., 1994; Pousa et al., 2017) .
Schizophrenia is currently diagnosed solely on the expression of subjectively interpreted symptoms (American Psychiatric Association, 2018; World Health Organization, 1992) , where a host of different factors can inform diagnosis. "Positive" psychotic elements, such as delusions and hallucinations, likely bring a patient to the attention of the healthcare system, and existing antipsychotics can fairly successfully moderate these symptoms (Leucht et al., 2009 (Leucht et al., , 2017 . However, the schizophrenic syndrome is also composed of "negative" and "cognitive" elements (Kay, 1990; McGlashan and Fenton, 1992; Tandon et al., 2009) , that may ultimately be more damaging to the longterm health outlook of the patient (Aleman et al., 2017; Green, 1996; Patel et al., 2015) . Negative symptoms refer to a reduction from a baseline functional capacity, such as apathy, flat affect, and isolation/ social withdrawal (Kirkpatrick et al., 2006; Winograd-Gurvich et al., 2006) . Cognitive symptoms encompass symptoms defined more precisely by their neuropsychological nature. Several recent collaborative efforts have attempted to systematise and formalise neuropsychiatric research in this area, such as the National Institute of Mental Health-sponsored MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) and CNTRICS (Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia) initiatives. These efforts have moved away from the symptom cluster approach and posited a more precise cognitive framework in which to study the schizophrenic syndrome (Carter and Barch, 2007; Kern et al., 2008; Marder, 2006; Marder and Fenton, 2004; Nuechterlein et al., 2008) . In comparison to the AD field, schizophrenia research has made significant progress in attempting to deconstruct the disease into more quantitative neuropsychological endpoints, although the syndrome itself does not have any robust neuropathological hallmarks or pathological biomarkers of diagnostic utility (Scarr et al., 2015) .
Overlapping symptoms in Alzheimer's disease and schizophrenia
Potential commonalities between AD and schizophrenia are most apparent when considering the presentation of NPS. In AD, NPS are highly prevalent and considered to accelerate disease progression and interfere with treatment effects to worsen prognosis for those afflicted (Barton et al., 2016; Finkel et al., 1996; Lyketsos et al., 2011; Steffens et al., 2009) . It has been estimated that more than 80% of probable AD patients will also exhibit at least one NPS (Lyketsos et al., 2002) . The most widely used measure of NPS in AD research is the Neuropsychiatric Inventory (Cummings et al., 1994) , which assesses several domains of behavioural functioning, including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity, nocturnal disturbance and eating abnormalities (Cummings, 1997) . A recent metaanalysis underscored apathy as the most prevalent NPS in AD, also associated with the severest cognitive impairment (Zhao et al., 2016) .
Table 1
Prevalence of Subjective Sleep Disturbance in Community-Dwelling Patients with Alzheimer's disease.
Other prevalent NPS in AD include depression, aggression, anxiety and sleep disturbance. The aggregated prevalence of sleep disturbance in AD patients has been estimated to be 39% in a recent meta-analysis including data from 48 studies (Table 1) but there is heterogeneity across studies, perhaps related to variation on disease duration, severity, age, medication, etc., and the tools used to assess sleep disturbance (Carpenter et al., 1996; McCurry et al., 2000; Rebok et al., 1991; Zhao et al., 2016) . In schizophrenia, psychosis and negative symptoms are defining features of the disease. In addition, complaints of sleep disturbance are a very common prodromal symptom preceding the first psychotic episode for most schizophrenic patients (Tan and Ang, 2001; Yung and McGorry, 1996; Zanini et al., 2013) . Thereafter, depending on illness duration and disease severity, many patients will continue to exhibit sleep disturbance (Chan et al., 2017) . It might not be unreasonable therefore to assume that apathy in AD may share overlapping features with negative symptoms in schizophrenia (Chase, 2011; Weiser and Garibaldi, 2015) , as might aspects of psychosis and sleep disturbance share common biology between each disease. However, there are significant shortcomings from published studies to be able to make strong conclusions about these relationships at present, and certainly not enough data to be able to redefine diagnostic boundaries of either disease. Taking sleep disturbance as an example, this review will focus on this issue, highlighting technical issues to overcome, describing what is known about commonalities in sleep disturbance between each disease, and suggesting what future work might need to be done in an attempt to redefine the boundaries of these diseases.
Assessment of sleep and circadian rhythmicity
Methodology
Sleep has several dimensions and can be quantified in many different ways (Fig. 1) . Appropriate parsing of these dimensions will inform the discussion about the nature of sleep disturbance in psychiatric and neurological disorders. Sleep exists as 1) a subjective experience, i.e., subjective sleep quality, sleep sufficiency, sleepiness; 2) as an observed behaviour, e.g., the restlessness or night wandering noted by the bed partner or caregiver; 3) as an objectively assessed behaviour, e.g., by actigraphy or polysomnography (PSG); 4) as an expression of circadian organisation.
The subjective experience of sleep can be assessed by sleep diaries and questionnaires such as the consensus sleep diary (Carney et al., 2012) , the Karolinska sleep diary (Åkerstedt et al., 1994) , the Karolinska Sleepiness Scale (Åkerstedt and Gillberg, 1990) , the Epworth Sleepiness Scale (Johns, 1991) , and the widely used Pittsburgh Sleep Quality Inventory (Buysse et al., 1989) , amongst others. These tools provide information on the subjective quality of sleep and sleepiness, as well as the timing and duration of sleep. However, they have not been developed in the context of psychiatric and neurological disorders and therefore may not be appropriate for all patients in this context. In fact, in many studies of sleep disturbance in patient populations and AD in particular, "custom made" tools or informal assessments are used (Table 1) . Whereas these custom approaches may capture relevant aspects of the specific disease, they do not facilitate comparison across studies and conditions. Interviews with carers and/or partners can provide insight into both the sleep of the patient, as well as the impact of the sleep of the patient on the carer, an aspect that recently has received more attention.
Objective quantification of nocturnal sleep can be obtained through actigraphy or PSG. Actigraphy measures rest and activity, and actigraphy of nocturnal sleep has shown reasonable concordance with PSG for the classification of wakefulness vs. sleep in healthy controls and insomnia patients (Marino et al., 2013) . However, accuracy of this sleep-wake classification has not been assessed in AD and schizophrenia. Furthermore, many new actigraphy based devices entering the market have not been validated at all. Actigraphy cannot quantify stages of sleep such as rapid-eye movement (REM) sleep, non-rapid-eye movement (NREM), sub-stages of Slow Wave Sleep (SWS), and specific R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 electroencephalographic (EEG) phenomena such as slow waves and sleep spindles. These brain states and phenomena can only be quantified by PSG recording (Box 1). In practice, three variables are considered in PSG assessments of sleep: these are the EEG, electrooculogram and electromyogram. Combinations of these variables define the states of waking, NREM sleep and REM sleep. Quantitative analysis of EEG (e.g. spectral analysis, wavelet analysis, non-linear approaches), can provide further information on changes in sleep and wakefulness associated with specific conditions. Addition of sensors to assess breathing movements, airflow, limb movements and heart rate are used to assess specific sleep disorders such as obstructive and central sleep apnoea, and periodic limb movements. Video recordings may be used to assess abnormal movements and REM sleep behaviour disorder. Whereas sleep has long been viewed as a global brain state, more recently attention has been drawn to local aspects of sleep. The essence of this "local view" of sleep is that during wakefulness particular brain circuits may be in a sleep-like state and during sleep some areas may be more or less asleep than other areas (Andrillon et al., 2011; Nir et al., 2017; Siclari and Tononi, 2017; Siegel, 2001) . High density EEG allows assessment of topographical/ local changes and can also be used to assess network properties such as coherence and global field synchronisation. Application of high density EEG has rarely been used in the context of sleep research in psychiatric and neurological disorders and obviously is difficult to implement in the home environment, but nevertheless holds promise for furthering our understanding of changes in sleep (DʼAgostino et al., 2018) . Several recent developments such as new electrode designs, miniaturisation of EEG amplifier and data storage technology, signal analysis and machine learning approaches which can identify sleep stages from fewer electrodes/variables, have led to the prospect of long-term EEG based sleep monitoring in real life settings (Debener et al., 2015; Pillay et al., 2018) .
Whereas the approaches discussed so far emphasize assessment of the major nocturnal sleep episode, they do not necessarily focus on the timing of sleep, which may include broken nocturnal sleep and daytime Sleep has many dimensions and various tools and approaches are used to capture these dimensions. Subjective assessments provided by patients and/or partners/caregivers via interviews and/or using customised questionnaires have highlighted differences in perception between patients and caregivers. While these tools allow the evaluation of several aspects of sleep (e.g., sleep quality, duration, daytime sleep and sleepiness), they do not facilitate comparison across studies and disorders as they are often tailored for specific psychiatric or neurological patient populations. Objective assessments are primarily based on actigraphy and polysomnography. Actigraphy allows the capture of 24-h rest-activity rhythms on a longterm basis and in a home-based environment. Polysomnography (electroencephalogram/electrooculogram/electromyogram) is still primarily performed in a laboratory/clinical research environment. It can distinguish between vigilance states (waking, NREM and REM sleep), quantify them, and also with quantitative EEG analysis can evaluate EEG hallmarks reflecting changes in brain activity and underlying mechanisms. EEG: electroencephalogram; EMG: electromyogram; EOG: electrooculogram.
Box 1
Vigilance states (•) and characteristic EEG hallmarks (○) in humans.
• Wakefulness ○ Active wake: beta rhythms (> 14 Hz) ○ Quiet resting state: alpha rhythms (8-12 Hz) ○ Drowsiness: theta rhythms (4-7 Hz)
• NREM sleep is subdivided in 3 stages (N1-3):
• N1: theta rhythms (4-7 Hz) • N2: • N3 (also known as deep SWS): slow waves (delta rhythms 0.5-4.5 Hz)) • REM sleep (also known as paradoxical sleep) • Theta, alpha and beta rhythms (> 14 Hz) naps within the 24-h cycle. Longitudinal continuous assessment of activity through actigraphy can provide a quantification of the circadian organisation of sleep. Detailed analysis of circadian rhythmicity may require collection of time series of physiological markers such as core body temperature, melatonin and cortisol although implementation of the required methodology in a home and patient setting is obviously challenging. Quantification of circadian organisation through a new generation of wearables collecting multiple variables holds promise Walch et al., 2016) although validation of the devices and algorithms to quantify circadian organisation is often lacking.
Relevance of different sleep measures
Within the general population, the subjective experience of sleep and its disturbance is one of the most significant determinants of quality of life (Strine and Chapman, 2005) . Always feeling tired, or excessive daytime sleepiness, is a common complaint and often a consequence of insufficient or disrupted sleep (Hasler et al., 2005) . Complaints of poor sleep quality and excessive sleepiness are associated with cognitive decline (Blackwell et al., 2014; Jaussent et al., 2012; Waller et al., 2016) . Subjective quality of sleep is associated with the consolidation of sleep, i.e., the inverse of the number of sleep interruptions and wake after sleep onset occurrences, and REM sleep (Della Monica et al., 2018; Kaplan et al., 2017) . Thus, poor subjective sleep quality and excessive daytime sleepiness are sensitive and early indicators of sleep disruption.
Nocturnal sleep timing in healthy adults is regular, with a 7-8 h sleep duration being considered optimal (Consensus Conference Panel et al., 2015) . Both self-reported short (< 6 h) and long sleep durations (> 9 h) are associated with negative health outcomes (Matricciani et al., 2017; Westwood et al., 2017; Suh et al., 2018) and cognitive decline (Lo et al., 2016) . In healthy adults, sleep generally occurs as one consolidated nighttime bout, with sustained wakefulness and alertness throughout the day, although occasional short daytime naps are not considered abnormal (Leng et al., 2017) . Indeed, self-reported excessive daytime sleepiness, napping, and in particular long naps may be predictive of cognitive decline (Cross et al., 2015) . Thus, subjective reports of abnormal sleep duration and timing and sleepiness provide relevant information.
PSG-based quantifications of sleep are usually based on summary statistics for variables such as Total Sleep Time (TST), NREM sleep time, N1, N2, N3 (SWS), REM sleep time, Wake After Sleep Onset, Number of Awakenings, Latency to Sleep and Latency to REM sleep. Alterations in these variables may reflect changes in brain circuits and neuromodulatory systems implicated in the generation of sleep and its substrates. Sleep is also associated with changes in cerebral blood flow, skeletal muscle tone, respiratory, cardiovascular, metabolic and endocrine variables, consciousness and mentation. Beneficial effects of healthy sleep or negative effects of disrupted sleep may be related to any of these variables. The value of assessing EEG activities is often related to their suspected contribution to brain function and in particular their roles in learning, memory and mood regulation. It seems fair, however, to state that currently the specific contribution of and the mechanism by which the various sleep stages, sleep continuity, sleep duration, specific sleep oscillations etc., to brain health has not been established (Boyce et al., 2017; Feld and Born, 2017; King et al., 2017) . Nevertheless, PSG assessment of sleep provides a comprehensive window on brain state and other physiological functions and may provide new biomarkers for cognitive decline.
Disturbances of sleep timing, duration and structure may also be indicators of disrupted circadian rhythmicity. Long-term recordings of restactivity cycles via actigraphy (Morgenthaler et al., 2007) or sleep diaries can be particularly informative about the extent of sleep duration and timing disturbances (e.g., extreme late or early sleep, extreme short or long sleep, excessive daytime napping) which may reflect disrupted circadian regulation of sleep. Assessment of circadian rhythmicity through markers such as the daily pattern of mood disturbances, agitation, or physiological markers such as melatonin (Magri et al., 2004) , cortisol, orexin (Liguori, 2017) , or the rhythmic expression of clock genes can provide information about the patency of temporal organisation. Assessment of circadian rhythmicity may be informative since its disruption can be predictive of cognitive decline (Zelinski et al., 2014) .
Specific methods of assessing sleep and circadian parameters have their strengths and weaknesses. For example, while PSG assessments of sleep in the sleep laboratory will provide detailed information on sleep structure, sleep continuity and EEG phenomena, it will not provide a reliable estimate of sleep patterns and TST per 24-h. This is a simple consequence of laboratory recording times being constrained. Actigraphy allows for assessment of these parameters in the real world environment although it should be kept in mind that even in the real world, rest-activity cycles may to some extent reflect imposed social schedules (e.g., in care homes) rather than the self-selected sleep schedule of the patient. Sleep disturbances and sleep disorders are common in mental disorders but are also co-morbid in many other conditions (e.g., cancer, multiple sclerosis, diabetes). Diagnostic criteria for sleep disorders do not necessarily include important physiological aspects of sleep such as the duration of SWS, REM sleep, number of sleep spindles and number of awakenings. Understanding of the contribution of sleep to brain function and pathophysiology will benefit from both an assessment of sleep disorders as well as sleep-physiology/phenomenology.
Measuring sleep parameters in the context of sleep disorders
Sleep and circadian disturbance in Alzheimer's disease and schizophrenia
Here, a series of studies on sleep and circadian disturbance in AD and schizophrenia have been compiled (Tables 1-4 ). Description and interpretation of sleep and circadian disturbance in patient populations is complicated by variation in disease severity, medication status and specificity and sensitivity of the tools used to quantify these disturbances. Thus, where data has been provided, these factors are specifically noted. The included clinical and preclinical studies were identified through a PUBMED search with the following search terms: "Alzheimer's disease + sleep"; "schizophrenia + sleep"; "Alzheimer's disease + circadian"; "schizophrenia + circadian", as well as searches related to specific sleep parameters: e.g. "sleep spindles + schizophrenia" and "REM + Alzheimer's disease". Articles were selected based on comprehensiveness, recency and accessibility.
Sleep in Alzheimer's disease
Subjective assessments
Subjective assessments of sleep in AD are often obtained through interviews with patients or caregivers (Table 1) . AD patients may not always have insight into their potential problems with sleep disturbance. For example, it has been reported that the perception by AD patients of their sleep quality is rather positive, with a large proportion of patients (83-91%) reporting their sleep as satisfactory (Ancoli-Israel et al., 1994; de Oliveira et al., 2014) . However, complaints of sleep disruption, difficulty falling asleep and night awakenings are also frequently reported, with prevalence ranging from 11 to 45%. How abnormal these prevalence estimates are is difficult to assess because in most studies an aged-matched control group was not included. Daytime sleep (i.e., napping) and sleep timing disturbances are also frequently reported. Overall, caregiver report analyses suggest an increased number of nocturnal awakenings and early morning awakenings, abnormal diurnal sleep-wake patterns, and excessive daytime sleepiness and napping (Carpenter et al., 1996; McCurry et al., 1999; Peter-Derex et al., 2015; Rebok et al., 1991) . To what extent this subjective sleep disturbance is a consequence of medication for AD, has a lower or higher than expected prevalence because of the use of sleep medication, cannot be reliably assessed from the existing literature.
Objective assessments
In studies in which subjective and objective assessments were obtained simultaneously, discrepancies between subjective reports of patients and objective measures of sleep by actigraphy become apparent even in the early stages of the disease (Most et al., 2012) . In the broadest sense, however, objective assessments of AD patients confirm that sleep is disrupted (Table 2 ). There is a general consensus from published actigraphy studies that AD patients experience a reduction in sleep efficiency and a higher number of awakenings. Estimates of changes in TST in AD are less consistent however, with some studies reporting reductions in TST, whilst others do not (Lauriola et al., 2017; Leger et al., 2017; Most et al., 2012; Musiek et al., 2018; Tanev et al., 2017; Weissova et al., 2016) . In a recent study using actigraphy in a carefully controlled group of patients with moderate AD, excluding a number of confounding factors (e.g., mixed diagnosis, comorbidities, pharmacological treatments), patients time in bed and TST were longer in AD (Wams et al., 2017) . All of these studies may however potentially be compromised by the unconfirmed validity of actigraphy for assessment of sleep in AD. PSG studies have confirmed an increase in the number of awakenings and in general report a reduction in TST. As mentioned, laboratory assessment of TST may not reflect TST in the home environment because recording periods are often limited to a conventional 8-hour nocturnal sleep period. PSG studies have shown that SWS and EEG Slow Wave Activity (SWA) is either unchanged or reduced in AD (Table 2) , while a recent study highlighted an association between carrying the apolipoprotein E ε4 allele and an increased N3 duration in the elderly (Tranah et al., 2018) . Sleep spindles are sometimes reported to be reduced in AD (Feinberg et al., 1967; Montplaisir et al., 1995; Reynolds et al., 1985; reviewed in Peter-Derex et al., 2015; Petit et al., 2004; Villa et al., 2015) although not assessed in many studies. Alterations in REM sleep parameters are frequently identified in AD. REM sleep duration or REM sleep percentages are generally reported as being decreased in AD, including medication-free patients, although in some studies REM was unchanged (Bliwise, 1993; Loewenstein et al., 1982; Vitiello et al., 1984) . Reports on changes in REM sleep latency are more variable, with some studies reporting an increase in latency to REM sleep, whilst others report no significant changes or a decrease (Bliwise, 1993; Bliwise et al., 1989; Loewenstein et al., 1982; Montplaisir et al., 1995; Prinz et al., 1982a, b; Reynolds et al., 1985) .
Changes in SWS and SWA in NREM sleep have received much attention. For example, in older adults, SWA was shown to be related to grey matter atrophy in medial prefrontal cortex and to mediate impairment in sleep-dependent memory (Mander et al., 2013) . In a subsequent study it was shown that reductions in SWA were correlated with β-amyloid burden (Mander et al., 2015) . Based on these and other data changes in SWS and SWA were recently proposed to be a promising biomarker for early diagnosis of AD (Mander et al., 2016) . Changes in EEG frequencies in other vigilance states have been considered in the context of AD as well. For example, EEG theta activity appears to be increased in AD patients in particular during REM sleep (Hassainia et al., 1997; Horvath et al., 2018) . A longitudinal study in the mild stage of AD reported that theta activity in resting EEG during wakefulness was the first parameter, and delta activity the last, to show alterations (Coben et al., 1985) . In this context it may be mentioned that several studies have described the presence of a diffuse, overall EEG slowing during wakefulness, observable even in early stages of AD (Horvath et al., 2018; Montplaisir et al., 1995; Peter-Derex et al., 2015; Petit et al., 2004; Prinz and Vitiello, 1989) . There are also more specific reports of theta activity increases and alpha activity decreases in waking EEG power in AD patients (Bliwise, 1993; Horvath et al., 2018) . EEG slowing in general refers to an increased dominance of low frequency oscillations, which may reflect a shift from alpha activity to theta and delta activity. Such a slowing may reflect either an increase in the amplitude of low frequency oscillations or a change in the frequency domain. While such EEG slowing phenomena may potentially be a sensitive marker of global changes in brain function/network integrity independent of vigilance state in AD patients, they may also make it more difficult to discriminate between vigilance stages in more formal sleep studies. Alternatively, these data may suggest that from an EEG perspective, the difference between waking and sleep states becomes less distinguished in AD.
Circadian alterations
Sleep diary and actigraphy studies have shown that sleep timing can be altered in AD, albeit with a great variability between patients that may relate to disease severity (Hatfield et al., 2004; Weissova et al., 2016) . Delayed wake time has been shown to be associated with higher dementia risk (Bokenberger et al., 2017) . Another indicator of altered circadian rhythmicity in AD patients is the deterioration of daily sleepwake pattern consolidation, with some patients exhibiting higher nocturnal and lower diurnal activities than normal. These changes can be R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 interpreted as a reduction in the strength or amplitude of circadian rhythmicity (Hatfield et al., 2004; Satlin et al., 1995; Wams et al., 2017) . It is thought that neurodegeneration in the suprachiasmatic nucleus, the circadian master clock, and alterations in melatonin levels contribute to circadian alterations in AD (Ferrari et al., 2000; Harper et al., 2008; Wu et al., 2003) . However, reduced or altered plasma melatonin profiles and circadian rest-activity patterns have not been observed in all studies (Weissova et al., 2016) . Cerebrospinal fluid (CSF) melatonin levels were found to be reduced in preclinical stages of AD, exhibiting a gradual decline with the course of AD neuropathology (Wu et al., 2003) , while cortisol rhythms seemed to remain relatively unchanged (Hatfield et al., 2004) . Some papers report that in severe cases of AD, a "sundowning" syndrome, described as a nocturnal worsening of some neuropsychiatric symptoms such as agitation, may be observed (for review, Bachman and Rabins, 2006; Bliwise, 1993; Iranzo, 2016; Peter-Derex et al., 2015) . However, due to the loose definition used across studies (Bliwise, 1993) , it is difficult to assess its prevalence. A carefully conducted study of the temporal distribution of agitation suggested that the sundowning syndrome may merely reflect a change of perception from caregivers, rather than an actual exacerbation of behavioural disruption near sunset or at night .
Other sleep disorders
Obstructive sleep apnoea (OSA) has been studied extensively in the context of AD and is suggested to be a predictor of disease development (Hita-Yanez et al., 2012; Polsek et al., 2018; Shi et al., 2017a,b; Liguori et al., 2017) . OSA is characterised by an intermittent cycle of repetitive pauses in breathing with associated hypoxia, which leads to numerous night-time arousals, and consequently, sleep fragmentation. OSA may cause or exacerbate excessive daytime sleepiness (Wennberg et al., 2017) and daytime napping in AD and may lead to sleep timing changes that may present as alterations in circadian organisation (Weissova et al., 2016; Zeitzer et al., 2013) . OSA has been recognised as a potential risk factor for AD (Sharma et al., 2018; Yaffe et al., 2011) . The prevalence of OSA has been reported to be as high as 70% in AD (Ancoli-Israel et al., 1991; Gehrman et al., 2003) . Individuals with AD have a five times higher risk of OSA than healthy controls (Emamian et al., 2016) , with OSA preceding cognitive decline usually by a decade (Sharma et al., 2018) . Treating OSA patients with continuous positive airway pressure reduces the onset or progression of mild cognitive impairment (MCI) (Sharma et al., 2018) , and may even attenuate the cognitive decline generally associated with mild to moderate AD (Troussiere et al., 2014) . However, the potential of using OSA as a predictive diagnostic and/or therapeutic target in AD has yet to be fully explored. In contrast to OSA, Periodic Limb Movements during Sleep (PLMS) is another sleep disorder with a high prevalence in older adults (Gehrman et al., 2002) ; however, its prevalence appears not to be increased in AD (Bliwise et al., 2012) .
Overall, changes in sleep fragmentation, REM and SWS in AD may be secondary to sleep disordered breathing or periodic limb movements. Likewise, excessive daytime sleepiness and lower cognitive status, as assessed by the Mini Mental State Examination Merlino et al., 2010; Rebok et al., 1991) in AD may be caused by sleep disorders.
Effects of AD medications on sleep
While pharmacological treatments for AD are currently very limited, these treatments affect neurotransmitter systems involved in sleepwake regulation and thereby are likely to have an impact on sleep in AD patients (Scammell et al., 2017) . Pharmacological treatments for AD include both acetylcholinesterase inhibitors and memantine, a noncompetitive NMDA receptor antagonist (Deardorff et al., 2015; Epperly et al., 2017; Herrmann et al., 2011) . Both treatments offer some symptomatic relief for a period but ultimately do not halt progression of the disease (Birks, R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 2006). PSG-based studies with anticholinesterase inhibitors, such as donepezil, document an increase in REM sleep percentage and reduced REM sleep latency that may effectively normalise REM sleep parameters in AD patients (Peter-Derex et al., 2015; Schweitzer and Randazzo, 2016) .
Effects of sleep medications in AD
A review of pharmacological treatments of sleep disturbance in AD (McCleery et al., 2016) highlighted that very few studies are available to provide guidance. The antidepressant trazodone may improve TST in moderate to severe AD patients, although no beneficial effect on sleep fragmentation was observed. Available evidence does not support the use of drugs acting at melatonin receptors (i.e., melatonin, ramelteon) for the treatment of sleep disturbance in AD (McCleery et al., 2016) . It is currently not known whether the dual orexin antagonists are effective in treating sleep disturbances in AD.
Sleep in Schizophrenia
Subjective assessments
The prevalence of sleep complaints is very high in schizophrenia patients (Table 3) . Subjective assessments of sleep in schizophrenic patients revealed difficulty in falling asleep, numerous night-time awakenings, and daytime napping (Poulin et al., 2010) . Furthermore, sleep duration is highly variable, ranging between 3-14.5 hours (median 8 h) in a self-report study (Faulkner & Bee, 2017 ). An in-depth interview study of how sleep was experienced, valued and perceived by schizophrenia patients revealed that "changes to sleep were interpreted as part of a perceived loss of normality relating to diagnosis". This analysis also indicated that sleep sometimes was experienced as an opportunity to escape (Faulkner and Bee, 2017) , which may relate to the very long sleep periods often observed. According to patient and family member reports, sleep disturbance such as disruption of sleep continuity is highly prevalent before the first episode of psychosis, and insomnia symptoms tend to intensify before relapse (Benson, 2015; Eisner et al., 2013) .
Objective assessments
Consistent with subjective assessments, most PSG nocturnal sleep studies report an increased sleep latency, higher number of awakenings, decreased TST and lower sleep efficiency in schizophrenia compared to healthy controls (Chan et al., 2017; Chouinard et al., 2004) (Table 4) . Any discrepancies between subjective and objective assessments of sleep duration in schizophrenia may, as in AD, potentially be an artefact of the scheduling of PSG-based laboratory assessment. Alterations in SWS and REM sleep durations, as well as REM sleep latency, are relatively inconsistent with studies reporting either a reduction in schizophrenia or no significant difference (Benca et al., 1992; Goder et al., 2006; Keshavan et al., 1998; Sarkar et al., 2010; Tekell et al., 2005) . Some of these discrepancies may be explained by the medication status at the time of sleep recordings (Cohrs, 2008) . Three meta-analyses have been published since 1992, the first of which reported a reduction in REM sleep latency as the only difference in schizophrenia (Benca et al., 1992) . The most recent meta-analysis, which included 31 PSG studies, showed that several sleep parameters are different in schizophrenia, i.e., reduced TST and sleep efficiency, increased sleep latency, more awakenings, and decreased percentage of SWS, REM sleep and REM sleep latency. However, these differences were dependent on the medication status and duration of drug withdrawal. Drug-naïve patients only showed differences in TST, sleep latency and sleep efficiency (Chan et al., 2017) . This is in accordance with another previous metaanalysis showing that sleep disturbances were more pronounced in neuroleptic-withdrawn patients compared to drug-naïve patients (Chouinard et al., 2004) . Medication status is therefore a very significant factor when considering the expression of sleep disturbances in schizophrenic patients.
Many studies have investigated sleep spindles and SWA in schizophrenia. Inconsistent findings have been obtained for SWA. By contrast, a decrease in spindles has been observed in medicated schizophrenia patients (Ferrarelli et al., 2007 (Ferrarelli et al., , 2010 Manoach et al., 2010; Wamsley et al., 2012) and in early stage drug-naïve patients (Manoach et al., 2014) , while no differences were observed in drug-withdrawn patients (Forest et al., 2007; Poulin et al., 2003; Van Cauter et al., 1991) . This suggests that spindles may be an early biomarker or endophenotype of schizophrenia (Ferrarelli and Tononi, 2017) .
Circadian alterations
Highly abnormal timing of sleep has been observed in approximately half of schizophrenic patients, with many patients not waking up before ∼15:00 . Abnormalities in physiological markers of the circadian timing system have also been reported in schizophrenia. Melatonin levels are decreased in schizophrenia sufferers compared to healthy subjects (Fanget et al., 1989; Vigano et al., 2001 ) and have been observed in both medication-naïve and medicated patients (Anderson and Maes, 2012; Monteleone et al., 1992) . As to the causes of this abnormal circadian rhythmicity, it should be kept in mind that many schizophrenia sufferers are unemployed and socially withdrawn. The absence of social constraints on sleep timing may lead to reduced exposure to daylight-the major synchroniser of the human circadian timing system-that may exacerbate circadian disturbance (Skeldon et al., 2017) . In a study in which schizophrenia patients were compared to unemployed healthy controls, circadian alterations as assessed by actigraphy were nevertheless observed in the patients (Wullf et al., 2012).
Other sleep disorders
Prevalence of insomnia is high and variable in schizophrenia, ranging from 19% to 100% depending on inclusion criteria and definition of insomnia (Kaskie et al., 2017) . A particularly comprehensive overview of this topic can be found in a review by Reeve and colleagues (Reeve et al., 2015) . Most recently, a prevalence of 25% for DSM-5 Insomnia Disorder in a population of schizophrenia outpatients was reported (Seow et al., 2018) . Several studies suggest that insomnia is a predictor of paranoia and hallucinations (reviewed in Reeve et al., 2015) , and may be associated with increased risk of suicide . Most studies of insomnia in schizophrenia have focused on its association with the first psychotic episode (Krystal, 2012; Davies et al., 2017) . In addition to insomnia, prevalence of OSA and sleep-related movement disorders in schizophrenia has been investigated (for review : Cohrs, 2008; Davies et al., 2017; Gupta and Simpson, 2015; Kaskie et al., 2017; Klingaman et al., 2015; Myles et al., 2016) . While many conflicting data are available, a meta-analysis showed a ∼15% prevalence of OSA in schizophrenia patients (Stubbs et al., 2016) which is not very different from the prevalence in the general population although prevalence rates are critically dependent on diagnostic criteria and sensitivity of sensors, which continue to change (Heinzer et al., 2016) . Although most clinicians report sleep disturbance in psychotic patients (Rehman et al., 2017) , more systematic screening may provide insight allowing the tailoring of treatments of sleep disturbance to improve delusions (Soehner et al., 2013; Spiegelhalder et al., 2013; Waters et al., 2015) .
Effects of antipsychotic medications on sleep
First and second-generation antipsychotics act on dopaminergic, serotonergic, α-adrenergic, cholinergic and histaminergic receptors, all of which have been implicated in control of sleep. The effects of antipsychotics on sleep-wake disturbance have been reviewed elsewhere (Cohrs, 2008; Schweitzer and Randazzo, 2016) . As mentioned above, a recent meta-analysis demonstrated that medication status, as well as duration of the drug-withdrawal period have a significant impact on Table 3 Prevalence of Subjective Sleep Disturbance in Community-Dwelling Patients with Schizophrenia. R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 sleep in schizophrenia patients (Chan et al., 2017) . Therefore, reported abnormalities of REM sleep and SWS in schizophrenia may be caused by medication rather than the disease itself.
Effects of sleep medications in schizophrenia
Pharmacological treatment and management of sleep disorders in schizophrenia have also received some attention (Gupta and Simpson, 2015; Kaskie et al., 2017; Klingaman et al., 2015) . Medications to treat sleep disorders in schizophrenia include antipsychotics, hypnotic drugs and melatonin. While some sleep disturbance such as insomnia may be improved, others, such as sleep movement disorder may be exacerbated, due to the action of antipsychotics on dopamine D2 receptors (Kaskie et al., 2017) .
Comparison of sleep disturbance between Alzheimer's disease and schizophrenia
When comparing sleep disturbance in AD and schizophrenia, there are very few ideal studies upon which to base conclusions. This is because of lack of standardisation of tools used to assess both subjective and objective sleep disturbance across each disease. For example, many assessments of subjective sleep disturbance are based questionnaires deliberately tailored to specific patient populations. Researchers in AD and schizophrenia may also emphasize different aspects of sleep when analysing data. For example, sleep spindles have received a lot of attention in schizophrenia but few AD researchers have focussed on this. Any attempt to compare sleep disturbance across disorders or to correlate with other symptoms will not be possible in the absence of standardisation. Another caveat in the comparison of sleep disturbance between AD and schizophrenia is the difference in the average age of these patient populations, with AD patients obviously being on average much older. Ageing is associated with major changes in sleep timing and sleep structure even in healthy individuals. Even if sleep in AD and schizophrenia are compared to age-matched controls it cannot be excluded that disease specific changes are not confounded by age differences. A final limitation of existing datasets is that changes in sleep are often presented in terms of statistical significance rather than in terms of effect sizes. The latter presentation would allow for a comparison of the magnitude of the observed effects in AD and schizophrenia.
Despite the limitations of existing datasets, several patterns emerge when comparing sleep-wake disturbance between AD and schizophrenia. Commonalities in sleep disturbance between AD and schizophrenia include sleep fragmentation, changes in sleep timing and circadian rhythm alterations. Reductions in SWS are reported in both conditions, although not in all studies. Differences between AD and schizophrenia are observed for clinical sleep disorders, with OSA being much more prevalent in AD while insomnia may be more prevalent in schizophrenia. However, the robustness of this conclusion is limited because insomnia as a complaint has not actually been assessed often in AD. Changes in sleep spindles are more often reported in schizophrenia, but this may in part reflect researcher bias. Altogether, the most prominent difference between AD and schizophrenia concerns REM sleep. REM sleep is often reported to be reduced, and in no single study has an increase in REM sleep been reported in AD, whereas in all but one schizophrenia study REM sleep was unchanged. This difference between AD and schizophrenia is unlikely to be related to medication because it was also observed when only considering drug free studies.
Contribution of sleep disturbance to other neuropsychiatric symptoms
Given the well-established detrimental impact of sleep fragmentation and sleep restriction on mood, attention and cognition in healthy individuals (Lowe et al., 2017) , the question arises whether sleep disturbance correlates with NPS in AD and schizophrenia. Potentially, sleep disturbance may emerge before clinical diagnosis and could correlate with early symptoms. By preceding more traditional symptoms, sleep disturbance may thereby be considered a predictive biomarker of the diseases. Sleep disturbance may also be associated with symptoms during the disease, remission, or predict relapse in the case of schizophrenia.
Alzheimer's disease
Sleep disruption leads to a higher risk of developing cognitive impairment and dementia (Benedict et al., 2015; Bubu et al., 2017) and the severity of sleep disruption is associated with the severity of dementia (Moe et al., 1995; Pat-Horenczyk et al., 1998) . Some crosssectional studies report an inverted U-shaped profile, with moderate AD patients having more impaired sleep than patients in early or advanced stages (McCurry et al., 2000; van Someren et al., 1996) . A recent population-based prospective study demonstrated that shorter REM sleep percentages and longer REM latencies several years prior to the incidence of dementia are both independently related with a higher risk for developing AD, while NREM sleep parameters showed no such associations . Each percentage reduction in REM sleep was associated with an approximate 9% increase in dementia risk, even after applying adjustments for vascular risk factors, depression, and medication use. REM sleep disruption during preclinical AD progression may therefore be underrated as a prognostic biomarker. A longitudinal study recently demonstrated that reduced REM sleep (and increased Stage 1 [N1]) was also a predictor of cognitive decline in non-demented older men (Song et al., 2015) . In a cross-sectional analysis of the association between sleep and cognition in healthy men and women aged 20-84, it was found that REM sleep as well as sleep continuity were associated with maintained 'accuracy' and executive function (Della Monica et al., 2018) .
Few studies have performed simultaneous assessment of sleep and other neuropsychiatric variables in AD (Lanctot et al., 2017) (Tables  1-4) . Sleep disturbance, total Pittsburgh Sleep Quality Index, sleep duration, time in bed at night and number of awakenings in AD were positively associated with apathy, the most frequently reported NPS in this disorder (de Oliveira et al., 2014; Mulin et al., 2011; Shin et al., 2014) . In fact, assessment of 24-h rest-activity patterns by actigraphy permits diagnosis of apathy in AD patients (Zeitzer et al., 2013) . Sleep disruption accompanied with apathy was identified as a strong predictor of functional impairment in AD (You et al., 2015) . AD patients presenting with sleep disturbance can also display aggressiveness/agitation, and other daytime behavioural issues although the robustness of this association remains unclear. Daytime sleepiness and napping were associated with more profound functional impairments including general cognitive, intellectual and abstractive function, verbal memory and fluency, spatial and visual memory, in mild and moderate AD patients (Bonanni et al., 2005) . Sleep disturbance also associated with the extent to which behavioural symptoms negatively impacted the patients or caregivers (Moran et al., 2005; Rebok et al., 1991) .
A decrease in the robustness of circadian rhythms in activity or delayed rhythms have also been associated with an increased risk to develop dementia (Tranah et al., 2011) . In terms of the relationship between sleep disruption and cognitive function, sleep disturbance in AD is associated with greater cognitive decline (Blackwell et al., 2014; Lim et al., 2013; Spira et al., 2014) and the onset of AD was at a younger age in patients with OSA (Osorio et al., 2015) . The degree of reduction in spindle density in mild cognitive impairment and AD correlates with the severity of memory impairment (Gorgoni et al., 2016; Westerberg et al., 2012) . Overall it can be concluded that despite the lack of systematic large-scale studies with standardised methodologies, there is emerging evidence for an association between sleep disturbance and neuropsychiatric symptoms in AD. Further standardisation of methodology may lead to more specific conclusions about the nature and extent of these associations.
Schizophrenia
Social withdrawal is a common neuropsychiatric symptom in schizophrenia and long time in bed periods and abnormal sleep-wake timing may be an expression of this, even before a diagnosis is made. For example, in socially withdrawn young individuals of whom 37% were ultimately diagnosed with schizophrenia and related disorders, disorders of the sleep-wake schedule were very common (> 70%) (Chauliac et al., 2017) . The association between PSG-assessed sleep characteristics, psychosis and positive psychotic symptoms has been investigated both in populations at risk as well as clinical cohorts (Reeve et al., 2015; Sarkar et al., 2010) . The most consistent findings in these studies were the positive associations between indices of increased REM sleep propensity (shorter REM latency, more REM sleep) and positive psychotic symptoms (Poulin et al., 2003; Sarkar et al., 2010 ; for review Reeve et al., 2015) , although this finding may be specific to medicated patients. Fewer studies have investigated the relationship between SWS and NPS in schizophrenia, and in several of these studies patients were medicated. SWS was reported to be inversely correlated with negative symptoms encompassing emotional withdrawal, blunted affect and poverty of speech (Keshavan et al., 1995 (Keshavan et al., , 1996 . Some studies document a correlation between spindle reduction in schizophrenia and the severity of psychosis (Ferrarelli et al., 2010; Manoach et al., 2004 Manoach et al., , 2014 Wamsley et al., 2012 ; for review Ferrarelli and Tononi, 2017; Manoach et al., 2016) . Furthermore, reductions in sleep spindles in NREM sleep correlated with impaired attention, poor performance in motor sequence, working memory, and declarative memory tasks in schizophrenic patients (Buchmann et al., 2014; Goder et al., 2015; Keshavan et al., 2011; Wamsley et al., 2012) . Interestingly, impairments in a verbal learning and memory test were also related to sleep spindle activity in first-degree relatives of schizophrenia patients (Schilling et al., 2017) . Overall, it can be concluded that many studies in schizophrenia report associations between aspects of sleep and other neuropsychiatric symptoms although the specificity and consistency of these associations and their dependency on medication status requires further investigation. Major limitations of the current studies concern the lack of standardisation across disorders, absence of longitudinal data and lack of unbiased approaches for the measurement of many sleep parameters. The available data nevertheless demonstrate the potential of investigating associations between sleep disturbance and neuropsychiatric symptoms in AD and schizophrenia.
Sleep disturbance in preclinical models of Alzheimer's disease and schizophrenia
A number of preclinical rodent models of AD and schizophrenia have been developed. Preclinical models of AD typically involve the experimental induction of either β-amyloid (Aβ) and/or tau pathology. Sleep studies in these AD models have documented a reduction in TST, NREM and REM sleep duration (Table 5 ). In several studies it was reported that sleep alterations arose prior to significant deposition of plaques and tangles and in some studies "rescue treatment" attenuated the sleep alterations (Table 5) . As a result of these findings, more work should be done to consider whether sleep may be a biomarker in early disease stages and/or potentially a marker of reversal of pathology. Fewer studies have evaluated sleep in schizophrenia models. These models target a broader variety of mechanisms including prenatal development, the vasoactive intestinal peptide receptor, or gene loci involved in schizophrenia (e.g., "Disrupted in schizophrenia 1" (DISC1); (Table 6) . A decrease in NREM sleep and REM sleep and increase in sleep fragmentation was observed in most of these studies (Table 6 ). In some of the animal models specific EEG oscillations, such as ripples and gamma activity, were quantified. Despite being implicated in memory consolidation and cognition, these oscillations are not easy to measure in human studies.
Overall, when it has been assessed, studies of sleep in preclinical models of AD and schizophrenia demonstrate sleep disturbances.
Comparisons across preclinical models and patient studies are hampered by different terminology and analysis methods. Nevertheless, the commonality of the neurobiological mechanisms underlying sleep and the prospect of comprehensive and longitudinal monitoring of this state does identify sleep as a promising target for furthering our understanding of psychiatric disorders.
Mechanisms linking sleep disturbance to NPS in AD and schizophrenia
The contribution of sleep to brain function has received considerable attention during the past decades and there is considerable evidence that sleep contributes to alertness, mood, sustained attention and memory consolidation. However, there is no consensus on how sleep exerts these positive effects. Several hypotheses have been proposed, and this section considers some of the putative mechanisms through which sleep may contribute to core and other neuropsychiatric symptoms in AD and schizophrenia.
Cellular mechanisms
Perhaps the most obvious mechanism to consider is that sleep disturbance directly influences the progression of molecular pathology in AD. Evidence for this hypothesis comes from both clinical and preclinical research. For instance, in the early stages of AD, Aβ levels in CSF display a diurnal rhythm, rising during wake and decreasing during sleep . Poor sleep in cognitively preserved adults with a parental history of sporadic AD correlates with higher levels of CSF biomarkers for AD, including Aβ42 and hyperphosphorylated tau (Sprecher et al., 2017) . Both of these findings suggest a potential relationship between sleep and amyloid pathology per se in humans. Similar changes are observed in rodent models. Manipulations such as chronic sleep restriction increase amyloid plaque deposition in an amyloid mouse model, while chronic treatment with a dual orexin antagonist (used clinically as a sleep-promoting agent) reduces plaque burden (Kang et al., 2009) . Longitudinal studies of a number of different AD mouse models (i.e. PDAPP, App Swe/PS1, triple transgenic hAPP/hTau/hPS1 mice) identify sleep and/or circadian alterations prior to the deposition of neuropathological hallmarks. Some of these preclinical transgenic sleep and circadian phenotypes replicate the sleep changes observed in AD sufferers (Table 5) . Furthermore, injection of Aβ oligomers into the brains of such mice disrupt rest-activity patterns as well as their ability to perform cognitive tasks (Kincheski et al., 2017) . These preclinical studies suggest that sleep and circadian disturbance may directly influence the rate of progression of pathological deposition in AD (Lucey and Bateman, 2014) , although one major limitation of this field is the sparseness of published literature. Very few preclinical studies have concomitantly assessed sleep disturbance with behavioural phenotypes, be they cognitive or otherwise, and then attempted to relate these measurements to synaptic integrity.
One cellular mechanism by which sleep may interact with protein pathologies in AD lies in its putative physiological role in solute clearance, via the recently described glymphatic pathway (Smith and Verkman, 2018) . This system provides active fluid transport dependent on aquaporin-4 channels through the brain (Iliff et al., 2012 ). An important recent paper used accumulation of tracer compounds to suggest that glymphatic clearance is more effective during sleep relative to wake (Xie et al., 2013) . This group then went on to suggest that glymphatic clearance during sleep contributes to the removal of toxic species, such as Aβ, accumulated during waking and further documented that sleep posture (lateral vs prone) had a substantial impact on the efficiency of this process in rodents (Lee et al., 2015) . The glymphatic hypothesis remains somewhat controversial with other studies challenging this notion (Smith and Verkman, 2017; Smith et al., 2017) . Several lines of evidence showed that clearance of β-amyloid occurs at the level of brain capillaries (Hartz et al., 2018 (Hartz et al., , 2016 Storck et al., 2016) . Recently, a critical role of meningeal lymphatic vasculature was Table 5 Sleep Disturbance Observed in Preclinical Models of Alzheimer's disease. R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 uncovered in the accumulation of parenchymal deposition of β-amyloid in mouse models of Alzheimer's disease (Da Mesquita et al., 2018) . Sleep and sleep loss has also been related to activity of the unfolded protein response (UPR) (Brown et al., 2017) . Dysfunction of the UPR has been implicated both in the neurodegenerative process of AD and in schizophrenia (Xiang et al., 2017) . Interestingly, drugs which modulate UPR activation have been shown to not only reverse cognitive deficits but also to reduce hippocampal atrophy in a dementia mouse model (Halliday et al., 2017) .
Neurotransmitter alterations
Specific neurotransmitter activities may also link sleep disturbance to the incidence of NPS in AD. Alterations in REM sleep parameters have often been ascribed to cholinergic deficits that are typically observed in AD (reviewed in Peter-Derex et al., 2015; Petit et al., 2004 ). However, it should be noted that the neurochemical regulation of REM sleep involves a variety of other neurotransmitter systems (Luppi et al., 2017; Saper and Fuller, 2017; Vetrivelan et al., 2016) and changes in REM sleep are therefore not necessarily primarily related to changes in the cholinergic system. An important neurotransmitter system in this context might be the orexin/hypocretin system, one of the key wakepromoting systems in the brain. Saporin lesions of orexin-producing neurons strongly implicate this system in behaviours related to arousal, attention and motivation, as well as goal-oriented behaviours (Boutrel et al., 2010; Wheeler et al., 2014) . Clinically, moderate to severe AD patients display elevated orexin levels in CSF, associated with total tau levels and sleep impairment (Liguori et al., 2014) , specifically REM sleep reduction (Liguori et al., 2016) . Orexin antagonists increase REM sleep in both rodents and humans (Bettica et al., 2012; Gotter et al., 2016) . Recent studies demonstrated that the effects of orexin antagonists on REM sleep were not mediated by basal cholinergic neurons Vazquez-DeRose et al., 2016) and increases in orexin in AD may well be related to reductions in REM sleep in this patient group (Bettica et al., 2012; Gotter et al., 2016) . As mentioned above, transgenic APPswe/PS1dE9 mice treated with a dual orexin receptor antagonist showed a reduced Aβ plaque burden (Kang et al., 2009) . These data imply that imbalance in the orexinergic system has the potential to contribute to sleep disruption in AD which may thereby affect disease progression.
Compared to AD, the multitude of genetic risk variants (Devor et al., 2017) and lack of any definitive causal mechanism in schizophrenia makes it much harder to address the question of the mechanistic links between sleep disturbance and NPS. However, monoaminergic circuits clearly play an important role, with the majority of clinically effective antipsychotic agents targeting blockade of dopamine, serotonin and histamine receptors. The heightened arousal state commonly observed in schizophrenia patients suggests an underlying issue with arousal control, which may be related to monoaminergic function. Recent evidence using optogenetic techniques has demonstrated an important role of the ventral tegmental area and specifically dopaminergic neurons in controlling wakefulness, motor function and wake-related behaviours (Eban-Rothschild et al., 2016) . Moreover, dopaminergic, noradrenergic and serotonergic transmission, as well as the dorsolateral prefrontal circuit, are common neural pathways contributing to negative symptoms and commonly implicated in both dementia and schizophrenia (Reichman and Negron, 2001; Winograd-Gurvich et al., 2006) . More specific genetic studies in this context are quite rare, although a recent study of a human 5HT 2B receptor mutation (HTR2B Q20*) indicated a link to impulsivity and incidence of early onset schizophrenia (Bevilacqua et al., 2010) . By way of comparison, 5HT 2B knockout mice demonstrate deficits in sensorimotor gating, selective attention, cognition and social interaction, as well as enhanced response to psychostimulants (Pitychoutis et al., 2015) . These animals also displayed disrupted sleep, with decreases in the amount of NREM sleep and reduced REM latency. Sleep fragmentation effects in R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112-137 schizophrenia patients have been recapitulated in a mouse model with disrupted synaptosomal-associated protein (SNAP-25), a gene that has been associated with schizophrenia (Oliver et al., 2012) . Otherwise, non-transgenic animal models (Table 6 ), such as those that affect early brain development, have proved more useful in identifying phenotypic changes similar to those in schizophrenia (Lodge and Grace, 2009 ). Investigation of sleep-wake activity in the methylazoxymethanol acetate (MAM) model revealed fragmentation of sleep and a decoupling of sleep spindles and hippocampal ripples (Phillips et al., 2012a,b) , in addition to cognitive and anatomical changes observed in schizophrenia (Brown et al., 2012) .
Mnemonic and cognitive processes
When evaluating mechanisms relating sleep disturbance and NPS, the potential importance of sleep and its phenomenology for cognitive processing and memory consolidation cannot be ignored (Dudai et al., 2015; Vorster and Born, 2015) . Sleep may provide a window for synaptic homeostasis to occur, a hypothetical process whereby synaptic weights that have altered as a function of experience and learning through the day are renormalized, allowing selected synapses to be strengthened whilst others are depressed . Both NREM and REM sleep processes likely play a role in synaptic homeostasis and memory consolidation (see e.g., Ritter et al., 2015) , although NREM sleep has received more study in this context. During NREM sleep, two electrophysiological signatures known as sleep spindles and hippocampal ripples occur (Buzsaki, 1998; Siapas and Wilson, 1998; Wei et al., 2016) . Sleep spindles are bursts of 12-16 Hz activity that originate in thalamic nuclei and can be relayed throughout the cortex as slow wave oscillatory activity. Recent evidence from human electrophysiological recordings demonstrate a strong link between thalamic spindles and cortical down-states (Mak-McCully et al., 2017) . Sleep spindle activity also coordinates with and potentially determines the expression of hippocampal ripples, bursts of high frequency (rodents:∼140-180 Hz; humans: 80-100 Hz) neuronal network activity that may represent compressed neuronal firing sequences from earlier periods during waking. In rodents, there has been much focus on hippocampal spatial memory as a model for exploring the role of slow waves and spindles in memory consolidation. These types of oscillatory activity provide optimal conditions for transfer of information from hippocampus to cortex (Maingret et al., 2016) , and disruption of hippocampal ripples will result in memory impairments in animal models (Sara, 2017; Latchoumane et al., 2017) . Spindles and SWA have been proposed to contribute to mechanisms underlying cognitive impairment and/or Aβ pathology (Kang et al., 2009; Mander et al., 2016; Roh et al., 2012) . However, like many of the other mechanisms described in this section, the study of spindle-ripple activity in the context of AD and schizophrenia has been very limited. In patients with mild cognitive impairment, stimulation of cortical slow oscillations using transcranial stimulation during sleep enhanced synchronization of slow oscillations and spindle power and was able to boost cognitive function (Ladenbauer et al., 2017) . Similarly, cortico-thalamic network dysfunction has been suggested as a target mechanism amenable to modulation by transcranial stimulation in schizophrenia (Pinault, 2017) . In schizophrenia, the genetic risk factor CACNA1-I encodes a calcium channel highly expressed in the thalamic circuits that generate spindles (Manoach et al., 2016) , suggestive of a mechanistic link worthy of further investigation. A recent study showed an association between CACNA1-I and sleep spindles in healthy adolescents (Merikanto et al., 2018) . Other mechanisms potentially involved in sleep-related memory consolidation processes include the cyclic adenosine monophosphate (cAMP) and mammalian target of rapamycin (mTOR) signalling (Havekes and Abel, 2017) , as well as changes in synaptic function and structure (de Vivo et al., 2017; Raven et al., 2018) .
Despite early work suggesting an important role for REM sleep in memory consolidation processes (Scullin and Bliwise, 2015; Siegel, 2001) , much less attention has been devoted to this topic. In mice, optogenetic disruption of EEG theta activity in the medial septum during REM sleep led to impairment of consolidation of spatial memory and fear-conditioned contextual memory (Boyce et al., 2016) . A requirement for REM sleep in the consolidation of learning related to danger and the extinction of fear responses has also been documented in humans (Menz et al., 2016) . There is growing evidence that REM sleep may specifically impact consolidation of emotional memories by contributing to the resolution of distress related to such experiences (Wassing et al., 2016) .
If sleep is fundamentally important for the stability of cognitive processes, it follows that a loss of sleep will be significantly detrimental to normal behaviour, a finding consistently confirmed by studies of sleep restriction in humans. Meta-analysis suggests that sleep loss may affect several neurocognitive functions, particularly those related to sustained attention and executive function (Lowe et al., 2017) . Furthermore, insomnia-like experimental sleep restriction paradigms can facilitate the development of psychotic experiences in human volunteers (Reeve et al., 2012) . Sleep disruption can induce paranoia, hallucinations, psychosis, cognitive disorganisation and working memory impairment. It can also be associated with increase in negative affect, depression, anxiety and stress (Reeve et al., 2012) . Several fMRI studies in humans have suggested that sleep deprivation decreases encodingrelated activities in the hippocampus, as well as connectivity to related areas of the cortex. Working memory dependent activity within the default mode network has been suggested to become unstable following sleep deprivation (Gujar et al., 2010) . In sleep deprived healthy individuals, increases in net synaptic strength and decreased ability to induce Long-Term Potentiation (LTP)-like plasticity has been observed, supporting the hypothesis that sleep loss will result in failure to reset associative synaptic plasticity (Kuhn et al., 2016) . One significant limitation is that human studies have so far focussed on the effects of a single night of sleep deprivation. Few have studied the effects of impaired sleep continuity or less acute disruption over a longer period. It should also be noted that there is considerable individual variability in response to sleep deprivation, the extent to which depends on the cognitive parameter being assessed (Frey et al., 2004) .
In summary, during sleep several plausible cellular mechanisms, including glymphatic clearance and the UPR, have been described that may directly affect pathology of AD and perhaps schizophrenia. Many of the neurotransmitter systems involved in the regulation of sleepwake activity are also directly impacted by each disease process and/or impacted by pharmacological treatments used. Specific aspects of sleep may also be directly involved in the effective processing of memories and learning events. Thus, if sleep is disturbed as a function of disease process, be it a timing, continuity or specific sleep stage disturbance, then this has the potential to impact upon cellular, synaptic and psychological processes that may then exacerbate disease. Datasets are promising but limited in this context and further elucidation of the relative contribution of specific aspects of sleep disturbance to each potential mechanism requires a neuroscience-oriented approach in both preclinical and clinical sleep research.
Perspectives and conclusions
This review has highlighted that there are several potentially important differences regarding the expression of sleep disturbance between AD and schizophrenia, and that not all patients may be affected equally by these symptoms. However, an ability to use this data to refine diagnosis of patients is greatly hampered by simple conceptual and operational problems. To further investigate the association between sleep disturbance, NPS and cognitive deficits in CNS disorders such as AD and schizophrenia, it will be important to improve several methodological aspects.
1 Implementation and validation of simultaneous assessment of sleep/circadian parameters and neuropsychiatric symptoms. This is a prerequisite to explore the interrelations between parameters such as TST, excessive daytime sleepiness and symptoms such as social withdrawal and apathy. Basic validation of specific test instruments for use in each specific disease state is often lacking. 2 Standardisation of commonly used descriptors of sleep disturbance. TST, which is one of the most basic measures of sleep behaviour may in some studies refer to the duration of PSG determined sleep during a laboratory session scheduled between 11 pm and 7am and in other studies refer to self or carer reported ad libitum nocturnal and diurnal sleep. Development of standardised reporting tools of nocturnal and diurnal sleep and wider implementation of actigraphy will greatly aid the quantification of sleep and circadian disturbance. Standardisation should extend to preclinical studies. 3 Standardisation of PSG based assessments of sleep. PSG studies performed in AD and schizophrenia have been primarily laboratorybased. To avoid the biases associated with laboratory studies and their scheduling constraints, development and implementation of new portable technology to record EEG using reduced montages in the home environment is needed (Bleichner and Debener, 2017; Lucey et al., 2016; Radha et al., 2014) . Additionally, many PSG studies focus on one single aspect of sleep phenomenology (e.g., SWS, spindles), and neglect other changes that may be happening.
Better quantification of REM sleep in this context may be critical given the potential difference between AD and schizophrenia, although most recent literature does not even make a distinction between phasic and tonic REM sleep. Standardisation should extend to preclinical studies. 4 Standardisation of screening for co-morbid sleep disorders.
Screening for sleep disorders such as sleep apnoea, periodic limb movements and insomnia should be part of the basic screening battery in any protocol assessing neuropsychiatric parameters in AD and schizophrenia. Sleep disorders may be differentially associated with each disease and thereby complicate any attempt to reclassify patients according to other objective biological parameters. 5 Wider application of quantitative EEG analysis approaches.
Higher density EEG recordings may be useful for the detection of local/topographical aspects of sleep. Longitudinal sleep recordings may capture the disorder trajectory more effectively and potentially help resolve subtypes of patients currently diagnosed with AD or schizophrenia. Secondary analyses such as the link between the waking EEG and the sleep EEG, coherence, global field synchronisation, connectivity, network properties, should provide valuable information and potentially provide insights into causative pathway contributing to the overlap with other neuropsychiatric symptoms. 6 Analyses of other physiological variables that change with sleep. For example, measurement of parameters such as heart rate, parasympathetic versus sympathetic tone are needed to capture the influence of sleep disturbances on physiological processes which may impact on the restorative function of sleep.
Attempting to differentiate AD and schizophrenia patients presenting clear sleep and circadian disruption from those with less pronounced disruption may provide insights into the association with other neuropsychiatric and cognitive symptoms in these disorders. Efforts like the PRISM initiative (Kas et al. 2018 , this issue) need to consider standardised collection of sleep parameters as being core to any attempt to objectively reclassify psychiatric and neurological disorders. Gaining further insights into the nature and extent of sleep disturbance in psychiatric and neurological disorders may have direct beneficial effects of the management of these disturbances. This should increase not only the quality of life of patients but also of their caregivers. It may offer insights into novel mechanisms and targets for drug development not only to delay but also to potentially prevent disease development and non-pharmaceutical interventions to neuropsychiatric and cognitive deficits in these disorders. Such approaches may not only lead to a better understanding of the association between sleep and brain function in these patient populations but also provide clues to the mechanisms by which sleep contributes to brain health across the lifespan.
